Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Current Liabilities for 16 consecutive years, with $133.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 18.46% to $133.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.8 million, a 18.46% decrease, with the full-year FY2025 number at $133.8 million, down 18.46% from a year prior.
  • Total Current Liabilities was $133.8 million for Q4 2025 at Myriad Genetics, down from $148.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $271.0 million in Q2 2021 to a low of $119.7 million in Q2 2022.
  • A 5-year average of $167.8 million and a median of $152.7 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 55.83% in 2022, then surged 84.71% in 2023.
  • Myriad Genetics' Total Current Liabilities stood at $204.3 million in 2021, then crashed by 32.84% to $137.2 million in 2022, then increased by 13.63% to $155.9 million in 2023, then grew by 5.26% to $164.1 million in 2024, then decreased by 18.46% to $133.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Total Current Liabilities are $133.8 million (Q4 2025), $148.0 million (Q3 2025), and $199.9 million (Q2 2025).